UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
VANCOUVER, BC, June 13, 2025 /CNW/ – UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation.
The two newly funded platforms are:
International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for patients.Total Grant Awarded: $1,866,750
The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain disorders.Total Grant Awarded: $4,845,000
'This platform represents a critical step toward advancing spinal cord injury research globally,' said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. 'By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients.'
'With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience,' said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. 'By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments.'
These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders.
'The UBC neuroscience community is grateful for Brain Canada's continued support,' said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. 'These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan.'
Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: 'By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives.'
These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month.
Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape.
'Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries,' said the Honourable Marjorie Michel, Minister of Health. 'Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 days ago
- Malaysian Reserve
Peer-Reviewed Study Validates Accuracy of SANSA Home Sleep Apnea Test
ATLANTA, Ga., June 17, 2025 /PRNewswire/ — Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced that the clinical validation study of its SANSA home sleep apnea test has been published in Frontiers in Neurology (Volume 16, 2025; doi: 10.3389/fneur.2025.1592690). The multicenter, prospective trial confirms that SANSA delivers comparable performance to in–lab polysomnography (PSG), the recognized gold standard for obstructive sleep apnea (OSA) diagnosis. The study, titled 'Polysomnography validation of SANSA to detect obstructive sleep apnea,' included 340 participants across seven U.S. clinical sites. SANSA's close agreement with PSG combined with its simple, single-point-of-contact, hands-free design positions it as an efficient and versatile solution to diagnose and monitor OSA. Study highlights include: Scale and diversity: Investigators highlighted the generalizability of the study results due to its large, diverse group of participants across seven academic and community sleep centers using different PSG protocols, exceeding that of most other home sleep testing study validations. Diagnostic accuracy: High apnea-hypopnea index (AHI) correlation with consensus PSG (91%), along with sensitivity of 88% and specificity of 87% for detecting moderate-to-severe OSA (AHI ≥ 15 events/hour) Total sleep time assessment: Correlation of R = 0.82 between SANSA and PSG-derived measures, with sleep epoch classification accuracy of 87% 'This publication represents an important milestone in the clinical validation of SANSA,' said Dr. Cathy Goldstein, MD, principal investigator on the study, professor of Neurology at the University of Michigan Sleep Disorders Center, and former chair of the American Academy of Sleep Medicine's Artificial Intelligence in Sleep Medicine Committee. 'As providers seek more efficient and scalable ways to diagnose sleep apnea, these findings reinforce that SANSA can deliver reliable, high-quality data without the complexity of traditional home sleep apnea testing devices.' The SANSA platform uses a wireless chest-worn patch to collect multi-parameter physiological data without the need for phone apps or technician setup. By simplifying testing, SANSA aims to expand access to timely diagnosis and treatment for millions of Americans with undiagnosed sleep apnea. The embedded reference electrocardiogram (ECG) within SANSA's suite of sensors also enables concurrent measurement of cardiac signals—opening new avenues for broader clinical applications. About Huxley MedicalHuxley Medical, Inc. is a privately held medical technology company on a mission to develop diagnostic solutions that streamline care for any patient anywhere. The company has received funding from the National Science Foundation, National Institutes of Health, Georgia Research Alliance Venture Fund, Invest Georgia, Georgia Tech Foundation Research Impact Fund, and Duke Capital Partners to translate its growing technology portfolio. To learn more, visit or email info@ Research manuscript: Media ContactBrennan TorstrickChief Scientific OfficerHuxley
Malaysian Reserve
13-06-2025
- Malaysian Reserve
UBC researchers awarded more than $6.5 million from Brain Canada to advance neuroscience research
VANCOUVER, BC, June 13, 2025 /CNW/ – UBC Faculty of Medicine researchers have been awarded more than $6.5 million from Brain Canada's Platform Support Grants program to support two pioneering neuroscience research platforms. The funding will help accelerate discovery and foster open science, positioning Canada at the forefront of global brain and spine health innovation. The two newly funded platforms are: International Spinal Cord Injury Biobank (ISCIB): Promoting Global Spinal Cord Injury Research Through Human Biobanking, led by Dr. Brian Kwon, which will expand access to vital human biological samples for spinal cord injury research, enabling researchers worldwide to advance treatments and improve outcomes for Grant Awarded: $1,866,750 The University of British Columbia Genes, Cells and Circuits (UBC-GC2) Platform for Next-Generation Multiscale Brain Research, led by Dr. Mark Cembrowski, which will integrate state-of-the-art technologies to map brain function and connectivity from molecules to entire circuits, unlocking insights into complex brain Grant Awarded: $4,845,000 'This platform represents a critical step toward advancing spinal cord injury research globally,' said Dr. Brian Kwon, a Professor in the Department of Orthopaedics and the Director of ICORD. 'By providing access to high-quality human biosamples, we're enabling researchers worldwide to develop and test new treatments that could dramatically improve quality of life for patients.' 'With the UBC-GC2 platform, we're bridging the gap between molecular biology and systems neuroscience,' said Dr. Mark Cembrowski, an Associate Professor in the Department of Cellular and Physiological Sciences. 'By integrating cutting-edge technologies, we'll be able to study brain function at an unprecedented scale and resolution. This will not only advance our understanding of brain disorders but also open new avenues for treatments.' These platforms exemplify UBC's commitment to advancing neuroscience and fostering collaboration within and beyond Canada's borders. 'The UBC neuroscience community is grateful for Brain Canada's continued support,' said Dr. Lynn Raymond, Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC. 'These investments will strengthen our capacity to deliver world-class research and transform brain health for people across the lifespan.' Viviane Poupon, President and CEO of Brain Canada, emphasized the importance of these initiatives: 'By supporting these cutting-edge platforms, Brain Canada is building the infrastructure that will accelerate brain and spinal cord research and foster open science collaboration. We're proud to partner with UBC to drive innovations that will impact millions of lives.' These two platforms are part of Brain Canada's broader Platform Support Grants (PSG) initiative, which has already invested in numerous projects across Canada to empower researchers with shared tools, data resources, and collaborative opportunities. The full list of funded platforms will be unveiled later this month. Brain Canada is contributing over $18 million in this year's PSG program through the Canada Brain Research Fund (CBRF), funded by Health Canada, as well as matching donations from sponsors for a total investment of $36.8 million. By enabling access to cutting-edge tools and specialized skills beyond the reach of individual researchers, the PSG program plays a vital role in strengthening the research landscape. 'Research and innovation are essential to unlocking new treatments, improving recovery, and enhancing quality of life for people affected by brain health issues and injuries,' said the Honourable Marjorie Michel, Minister of Health. 'Through the Canada Brain Research Fund, the Government of Canada is very pleased to support these new neuroscience research platforms, which bring together experts from different fields, integrate cutting-edge technologies and focus on improving patient outcomes.'
Malaysian Reserve
06-06-2025
- Malaysian Reserve
Changing Systems, One Story at a Time: National Summit Reimagines Obesity Care Through Community, Connection, and Compassion
TORONTO, June 6, 2025 /CNW/ – Sunday, June 8, 2025 — National advocacy organization Obesity Matters will host the Your Health Matters Summit 2025 at the historic Old Mill Toronto, with virtual access available across Canada. This one-day, community-powered event is creating space for real stories, honest conversations, and stigma-free care — putting people, not just conditions, at the center of health and wellness. With the theme 'Inspire Change. Build Connection. Advance Wellness.', the summit brings together healthcare professionals, lived experience advocates, and community leaders to explore how we can shift the narrative around health — from judgment to empathy, and from isolation to meaningful support. 'Obesity isn't a character flaw — it's a chronic condition that deserves empathy, science, and dignity,' says Priti Chawla, Executive Director of Obesity Matters.'This summit is about rewriting the narrative — one story, one connection, one person at a time.' Program highlights include: Dr. Sean Wharton and Dr. Gillian Mandich on self-compassion and emotional resilience Dr. Megha Poddar on hormone health across life stages Dr. Peter Selby facilitating a storytelling session with patient advocates Dr. David Macklin on Resilience… The Secret Skill to Success A featured session on Body Image, Stigma, and the Age of Anti-Obesity Medication will be led by Dr. Sandy Van and Sandra Elia, Chair of Obesity Matters. 'We can't let outdated ideals or social media define what health looks like,' says Dr. Sandy Van.'In the era of obesity medication, the pressure to meet unrealistic appearance goals can take a real psychological toll. Effective care must be rooted in evidence, with compassion for both the body and the mind.' 'For too long, people have carried the weight of shame when what they needed was care. At this summit, we are rewriting that story — one rooted in love, science, and the belief that every person deserves access to evidence-based treatment.' — Sandra Elia, Chair, Obesity Matters For full program details, visit:
